Long-term follow-up for Q-Cells recipients
Part of Brain & nervous system, Cancer, Immune system & allergy, Infections clinical trials.
This study is for people who have already received Q-Cells treatment. It does not test new treatments; instead, it checks on your health over a long time to see how you are doing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already received Q-Cells treatment in a previous study or treatment program.
- You must agree to sign a consent form that explains the study and allows your health information to be used.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if transplanting special cells into the spine is safe for people with transverse myelitis (a rare spinal cord inflammation) that has caused long-term weakness or trouble walking. It aims to see if these cells can help improve function.
This study tests a new treatment called CC-97540 (a type of CAR T-cell therapy) for people with neuromyelitis optica spectrum disorder (NMOSD), which is an autoimmune disease that affects the eyes and spinal cord. The goal is to see if this treatment is safe and tolerable.
This registry study will follow people who have received the CAR T-cell therapy equecabtagene autoleucel to monitor their long-term health and outcomes. It is open to those who completed or withdrew from an earlier study of this treatment.
This study is testing whether injecting special cells (called Q-Cells) into the spinal cord is safe for people with ALS. It's an early-stage trial, so the main goal is to check safety, but it might help slow down the disease in the future.
This study checks how people do long-term after stem cell transplant, cellular therapy, or gene therapy. It may help doctors track longer-term health effects and recovery and improve future care.
This study follows people who have already received a CRISPR CAR T cell therapy to monitor their long-term health and any side effects. It helps doctors understand how these treatments work over time.
Hear when a new Transverse Myelitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.